Merck & Co. and Daiichi Sankyo's cancer drug, patritumab deruxtecan, improved progression-free survival in a phase 3 trial for EGFR-mutated NSCLC patients.
Merck & Co. and Daiichi Sankyo announced that their cancer drug, patritumab deruxtecan, achieved its primary goal in a phase 3 trial for patients with EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with EGFR tyrosine kinase inhibitors. The drug showed a significant improvement in progression-free survival compared to standard chemotherapy. While overall survival data are still being evaluated, the safety profile aligned with prior studies.
September 17, 2024
8 Articles